Filter posts

Haves and Have Nots in Biotech Venture Capital

Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” …

Fireside Chat: “Everything we knew in science 10 years ago is wrong.”

The speed of scientific innovation these days is comparable to the PC innovation era of …

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials

Recent Tufts data show clinical trials typically take nearly twice as long to complete enrollment …

Fireside Chat: James Noble Says Go for IPO

“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had …

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

To even the most casual observer, 2015 has been a big year in the biotech …

BIO Investor Forum Session Recap: Precision Medicine: Leveraging National Genomic Databases for Ther...

As the price point for full genome analysis falls through the $1,000 per person milestone, …

BIO Investor Forum Newly Added Sessions - Digital Health Spotlights

We are pleased to announce that two “digital health spotlight” sessions have been added to …

See What’s New at the 2015 BIO Investor Forum

The 2015 BIO Investor Forum is just two weeks away, and it’s gearing up to …

Discover Trends and Investment Opportunities at the BIO Investor Forum

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event …

Congratulations to the 2015 Buzz of BIO at the BIO Investor Forum Winners!

BIO is pleased to announce the winners of the 2015 BIO Investor Forum Buzz of BIO …